Definition

  • Rare, severe multisystem disorder characterized by massive hepatocyte necrosis or profound functional impairment.
  • Diagnosis requires three core criteria:
    • Biochemical evidence of acute liver injury.
    • Hepatic-based coagulopathy unresponsive to vitamin K. Defined as prothrombin time >15 seconds or international normalized ratio >1.5 in presence of clinical encephalopathy; OR prothrombin time >20 seconds or international normalized ratio >2.0 regardless of encephalopathy.
    • Absence of preexisting chronic liver disease (exceptions include acute initial presentations of Wilson disease or autoimmune hepatitis).

Pathophysiology

  • Hepatocyte death/injury triggers massive release of bioactive substances and toxins, initiating multiorgan failure cascade.
  • Factor VII possesses shortest half-life (4-6 hours) among vitamin K-dependent factors; depletes earliest, rendering international normalized ratio a dynamic, sensitive marker of synthetic inadequacy.
  • Cerebral edema/Intracranial hypertension: Ammonia and inflammatory cytokines induce astrocyte swelling, altering intracellular fluid shifts.
  • Coagulopathy: Decreased synthesis of coagulation factors, protein C, protein S, and antithrombin.
  • Metabolic derangement: Hypoglycemia secondary to impaired gluconeogenesis, reduced glycogen stores, and impaired hepatic insulin clearance. Lactic acidosis results from impaired tissue perfusion and decreased hepatic detoxification.

Etiological Classification

Age CategoryCommon Etiologies
Neonates/InfantsGalactosemia, tyrosinemia type 1, gestational alloimmune liver disease (neonatal hemochromatosis), mitochondrial hepatopathies, hemophagocytic lymphohistiocytosis, viral (herpes simplex virus, cytomegalovirus, echovirus).
Children/AdolescentsAcetaminophen toxicity, viral hepatitis (A, B, E), autoimmune hepatitis, Wilson disease, indeterminate/idiopathic (40-50% of cases).

Clinical Manifestations

SystemSpecific Signs And Symptoms
General/HepaticProgressive jaundice, fetor hepaticus, rapid decrease in liver size (ominous sign indicating massive necrosis), abdominal pain, vomiting.
NeurologicalHepatic encephalopathy (irritability, sleep rhythm inversion, somnolence, combative behavior, decerebrate/decorticate posturing, coma), cerebral edema, seizures.
HematologicalBleeding diathesis (gastrointestinal hemorrhage), thrombocytopenia, aplastic anemia.
Renal/MetabolicHepatorenal syndrome, hypoglycemia, hypokalemia, hyponatremia, metabolic acidosis, respiratory alkalosis.
ImmunologicalHigh susceptibility to systemic infections (Staphylococcus aureus, Staphylococcus epidermidis, gram-negative organisms, fungal infections) secondary to impaired Kupffer cell and polymorphonuclear function.

Diagnostic Evaluation

Initial Screening

  • Complete blood count, comprehensive metabolic panel, transaminases, fractionated bilirubin, prothrombin time, international normalized ratio.
  • Ammonia, lactate, blood glucose, amylase, lipase.
  • Blood, urine, and sputum cultures (prior to antimicrobial initiation).

Etiology-Specific Assays

Suspected EtiologyDiagnostic Investigations
ViralHepatitis A IgM, Hepatitis B surface antigen/core IgM, Hepatitis C antibody/PCR, Epstein-Barr virus, Cytomegalovirus, Herpes simplex virus PCR.
MetabolicGalactose-1-phosphate uridyl transferase, urinary succinylacetone, plasma acylcarnitines, transferrin isoelectrophoresis.
AutoimmuneAntinuclear antibodies, smooth muscle antibodies, liver-kidney microsomal antibodies, serum IgG.
Toxic/DrugAcetaminophen levels, serum toxicology screen.
Wilson DiseaseSerum ceruloplasmin, 24-hour urinary copper, slit-lamp examination, Coombs-negative hemolytic anemia markers.

Differential Diagnosis Of Neonatal Liver Failure

EtiologyTransaminases (IU/L)Coagulopathy (INR)Ferritin (ng/mL)
Gestational Alloimmune Liver DiseaseNormal/mild increase (<100)Significant increase800 - 7,000
Hemophagocytic LymphohistiocytosisModerate/significant increase (>1000)Moderate/significant increaseSignificant increase (>20,000)
Mitochondrial HepatopathyModerate increase (100 - 500)Moderate/significant increaseVariable
Ischemic HepatitisSignificant increase (>1,000 - 6,000)Moderate/significant increaseVariable

Data derived from diagnostic profiles of neonatal hepatic failure.

Prognostic Scoring (King’s College Criteria)

Predicts mortality and guides urgent liver transplantation listing.

CategoryCriteria Mandating Transplantation
Acetaminophen-InducedArterial pH <7.30 (post-resuscitation) OR all three of: INR >6.5, creatinine >3.4 mg/dL, and Grade III/IV encephalopathy.
Non-AcetaminophenProthrombin time >100 seconds (INR >6.5) OR any three of: age <11 years, jaundice to encephalopathy >7 days, bilirubin >17.4 mg/dL (300 umol/L), prothrombin time >50 seconds (INR >3.5), drug toxicity etiology.

Note: In pediatric cohorts, isolated peak INR >4 demonstrates high sensitivity for mortality without transplantation.

Management Protocol

Intensive Supportive Care

  • Neurological: Maintain quiet environment, head elevation 30 degrees. Treat intracranial hypertension with 3% hypertonic saline, 20% mannitol, or transient hyperventilation. Avoid benzodiazepines.
  • Metabolic/Fluid: Utilize 10% dextrose-based maintenance fluids targeting euglycemia. Avoid fluid overload and Ringer’s lactate (impaired hepatic lactate metabolism).
  • Coagulation: Administer parenteral vitamin K. Restrict fresh frozen plasma or prothrombin complex concentrates exclusively to active bleeding episodes or prior to invasive procedures (allows accurate INR monitoring). Use proton pump inhibitors for stress ulcer prophylaxis.
  • Infection: Initiate broad-spectrum prophylactic intravenous antibiotics and antifungals. Add acyclovir for neonates pending viral diagnostics.
  • Renal/Ammonia: Implement continuous renal replacement therapy for hyperammonemia (>200 umol/L) or acute kidney injury. Administer lactulose or rifaximin.

Disease-Specific Pharmacotherapy

EtiologyTargeted Therapy
Acetaminophen ToxicityIntravenous N-acetylcysteine.
Gestational Alloimmune Liver DiseaseDouble volume exchange transfusion combined with intravenous immunoglobulin.
Tyrosinemia Type 1Nitisinone; dietary restriction of phenylalanine and tyrosine.
Autoimmune HepatitisSystemic corticosteroids.
Herpes Simplex VirusIntravenous acyclovir.
Wilson DiseaseCopper chelation (Penicillamine, Trientine).
GalactosemiaStrict lactose/galactose-free dietary formula.

Advanced Interventions

  • Liver Assist Devices: Cell-free cleansing devices or bioartificial liver systems utilized strictly as experimental bridging therapies to remove toxins (ammonia, cytokines) while awaiting transplantation.
  • Orthotopic Liver Transplantation: Definitive, lifesaving therapy for irreversible failure (advanced coma, King’s College criteria fulfillment). Absolute contraindications include fixed dilated pupils, systemic mitochondrial disease, and uncontrolled sepsis. Survival approaches 75% at 6 months post-transplantation.